bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 8.94M -4.3% |
| Revenue (ttm) | 5.66M -35.8% |
| Net Income | -15.88M |
| EPS | -5.89 |
| Shares Out | 4.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 172,996 |
| Open | 1.930 |
| Previous Close | 2.030 |
| Day's Range | 1.920 - 2.060 |
| 52-Week Range | 0.693 - 14.997 |
| Beta | -1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
Financial Performance
In 2025, bioAffinity Technologies's revenue was $6.16 million, a decrease of -34.18% compared to the previous year's $9.36 million. Losses were -$14.91 million, 64.9% more than in 2024.
Financial StatementsNews
BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year
Reports revenue $1.4M vs. $1.9M last year. “Our first quarter results demonstrate continued momentum for CyPath Lung in the marketplace. As more and more physicians adopt CyPath Lung and share…
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection ...
BioAffinity Technologies files to sell 497,483 shares of common stock for holder
17:09 EDT BioAffinity Technologies (BIAF) files to sell 497,483 shares of common stock for holder
BioAffinity Technologies launches new study to expand use of CyPath lung tech
bioAffinity Technologies (BIAF) announced a pilot study with Brooke Army Medical Center, BAMC, to evaluate the Company’s proprietary tests under development to identify specific inflammatory biomarker...
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AI--bioAffinity Technologies announces study with Brooke Army Medical Center to evaluate new diagnostic tests to improve treatment for asthma and COPD.
BioAffinity Technologies releases clinical case on CyPath Lung
bioAffinity Technologies (BIAF) released a new clinical case study illustrating how CyPath Lung, the Company’s noninvasive sputum-based diagnostic test, helped determine next steps for a high-risk pat...
New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--Patient case study in which CyPath Lung spared a high-risk patient with a suspicious nodule and elevated risk from an invasive biopsy,.
bioAffinity Technologies Transcript: Status update
Panelists noted challenges in pulmonary nodule assessment and limits of current risk models. CyPath Lung, a non-invasive sputum test, offers high sensitivity and negative predictive value, aiding risk stratification, reducing unnecessary biopsies, and improving reassurance. Its clinical use is expanding, with ongoing research to refine it.
BioAffinity announces CyPath Lung to be featured at Cleveland Clinic symposium
bioAffinity Technologies (BIAF) announces that its CyPath Lung test will be featured at the invitation-only “Advances in Early Lung Cancer Detection” symposium at the Cleveland Clinic in Cleveland, Oh...
bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual lung cancer symposium.
BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1
bioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic in the first quarter of 2026 exceeded internal projections and, based on preliminary unaudited data, achieved 1...
bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies' CyPath Lung Sales Surged 146% Year-Over-Year in Q1 2026, gaining traction in the U.S. addressable market of $3.58 billion.
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will host a webinar on April 8 with leading pulmonologists who will share their clinical experience with CyPath Lung.
New Case Study: bioAffinity Technologies' CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in physician decision-making and patient outcome.
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports financial results for FY 2025, including record revenue and unit sales for the CyPath Lung test for lung cancer.
BioAffinity Technologies initiates clinical study for CyPath Lung
BioAffinity Technologies (BIAF) announced initiation of the company’s planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage...
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer.
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AAAAI--bioAffinity Technologies presents research at AAAAI related to identifying drug antibody receptors in sputum for two leading asthma therapies.
BioAffinity announces study to expand CyPath Lung sample collection options
BioAffinity Technologies (BIAF) announced a study with Brooke Army Medical Center to validate the clinical utility of using the CyPath Lung diagnostic test to assess sputum samples obtained by trachea...
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BAMC--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
BioAffinity Technologies releases clinical case study on CyPath Lung test
bioAffinity Technologies (BIAF) released a new clinical case study in which its CyPath Lung noninvasive diagnostic test for lung cancer helped determine the appropriate treatment for a 79-year-old fem...
New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--In new case study, CyPath Lung spares elderly woman from an invasive procedure for a suspicious lung nodule discovered on a CT scan.
Clinical Utility of bioAffinity Technologies' CyPath® Lung Test Demonstrated in Real-World Case Study
SAN ANTONIO, Texas--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies shares a new case study that demonstrates how CyPath® Lung supports clinical decision-making in high-risk patients.
BioAffinity Technologies announces new appointments to Advisory Board
bioAffinity Technologies (BIAF) announced new appointments to its Medical and Scientific Advisory Board, including: David Ost; Daniel Sterman; and J. Scott Ferguson. The appointments reflect a planned...
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies appoints nationally recognized pulmonary and lung cancer authorities to its Medical and Scientific Advisory Board.